2022
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regressionDescribing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
Green A, Curtis H, Hulme W, Williamson E, McDonald H, Bhaskaran K, Rentsch C, Schultze A, MacKenna B, Mahalingasivam V, Tomlinson L, Walker A, Fisher L, Massey J, Andrews C, Hopcroft L, Morton C, Croker R, Morley J, Mehrkar A, Bacon S, Evans D, Inglesby P, Hickman G, Ward T, Davy S, Mathur R, Tazare J, Eggo R, Wing K, Wong A, Forbes H, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Smeeth L, Goldacre B. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. BMC Medicine 2022, 20: 243. PMID: 35791013, PMCID: PMC9255436, DOI: 10.1186/s12916-022-02422-0.Peer-Reviewed Original ResearchConceptsPositive SARS-CoV-2 testSARS-CoV-2 testBreakthrough COVID-19Vaccine breakthroughBreakthrough casesCohort studyIncidence rateCOVID-19COVID-19-related hospital admissionsCOVID-19-related deathsVaccine breakthrough casesRetrospective cohort studyChronic kidney diseaseCritical care admissionSARS-CoV-2 variantsDeath registry dataCorresponding incidence ratesRoutine clinical dataHigh rateMedian followVaccine waningCare admissionHospital admissionSecond vaccinationSecondary care
2021
UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, Mansfield KE, Rentsch CT, Douglas IJ, Mathur R, Wong AYS, Quint JK, Andrews N, Bernal JL, Scott JA, Ramsay M, Smeeth L, McDonald HI. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health 2021, 21: 484. PMID: 33706738, PMCID: PMC7948667, DOI: 10.1186/s12889-021-10427-2.Peer-Reviewed Original ResearchConceptsSevere COVID-19Health conditionsElectronic health recordsHigh riskRisk populationsCOVID-19Clinical Practice Research Datalink GOLDSevere COVID-19 diseaseSecondary care recordsChronic kidney diseaseHealth recordsChronic liver diseasePoint prevalence studyBinomial exact confidence intervalsOlder age groupsPublic health interventionsWorking-aged individualsCOVID-19 diseaseWorking-aged adultsUK prevalenceCurrent asthmaLiver diseaseCancer survivorsPoint prevalenceKidney disease